- About ASF
- What is Autism?
- How Common is Autism?
- Early Signs of Autism
- Autism Diagnosis
- Following a Diagnosis
- Treatment Options
- Beware of Non-Evidence-Based Treatments
- Autism and Vaccines
- Autism Science
- Quick Facts About Autism
- What We Fund
- Autism Sisters Project
- Baby Siblings Research Consortium
- Resources for Grantees
- Funding Calendar
- ASF Funded Research
- ASF Supported Findings
- Apply for a Fellowship
- Apply for a Research Accelerator Grant
- Apply for an Undergraduate Summer Research Grant
- Apply for INSAR Annual Meeting Travel Grant
- Get Involved
- Day of Learning
- Research Recap of 2017
- Contact Us
Research by Topic: Risperidone
Is Medication Information for Children with Autism Spectrum Disorder Monitored and Coordinated Across Professionals? Findings from a Teacher SurveyPublished March 1, 2013 in School Mental Health
This study examined school-based medication monitoring in children with ASD. Researchers found that less than half of teachers of medicated students were aware that students were taking medication and no teachers were communicating with prescribing physicians about student behavior and side effects. Since monitoring medication across settings helps physicians assess drug safety and effectiveness, the authors argue for increased communication among professionals.
This study analyzes the efficacy and secondary effects of the drugs, Risperidone and Aripipazole.
Treatments Show Promise in Reducing Autism-related Behaviors, but Some have Significant Side EffectsPublished April 4, 2011 in Agency for Heathcare Research and Quality
Some medical and behavioral treatments show promise for reducing certain behaviors in children with autism spectrum disorders (ASDs), but more research is needed to assess the potential benefits and harms, according to a new report funded by HHS’ Agency for Healthcare Research and Quality (AHRQ). The research results were published online in the journal Pediatrics.
Researchers at Vanderbilt University reviewed evidence regarding medical treatment of children 12 years old and younger with an Autism Spectrum Disorder (ASD). It was found that risperidone and aripiprazole for treatment of challenging and repetitive behaviors in children with ASDs. However, there are significant adverse effects of these medicines, including severe impairment or risk of […]
Moderators, Mediators,and Other Predictors of Risperidone Response in Children with Autistic Disorder and IrritabilityPublished April 1, 2010 in Journal of Childhood and Adolescent Psychopharmacology, Arnold et al
The National Institute of Mental Health (NIMH) Research Units on Pediatric Psychopharmacology (RUPP) Autism Network found an effect size of d = 1.2 in favor of risperidone on the main outcome measure in an 8-week double-blind, placebo-controlled trial for irritability in autistic disorder. This paper explores moderators and mediators of this effect. This study found […]